NXL Nexalin Technology, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1527352 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY76.7%
TTM net income YoY-8.0%
TTM EPS YoY108.1%
Revenue 3-yr CAGR29.2%
Net income 3-yr CAGR—
Margins
Gross margin82.4%
Operating margin-3,386.0%
Net margin-3,380.6%
FCF margin—
EBITDA margin—
Returns
ROE-372.6%
ROA-222.9%
ROIC (approx.)-406.6%
Asset turnover0.07x
Leverage & solvency
Liabilities / assets92.0%
Debt / equity0.00x
Current ratio0.69x
Interest coverage-179.02x
Cash quality & payout
Operating cash flow / net income0.67x
Accruals ratio-74.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $301,647 | $168,721 |
| Cost of revenue | $61,373 | $36,593 |
| Gross profit | $240,274 | $132,128 |
| R&D expense | $1.08M | $1.19M |
| SG&A expense | $4.40M | $4.23M |
| Operating income | -$8.39M | -$7.75M |
| Interest expense | -$8,240 | -$3,193 |
| Pretax income | -$8.22M | -$7.61M |
| Net income | -$8.22M | -$7.61M |
| EPS (basic) | -0.50 | -0.83 |
| EPS (diluted) | -0.50 | -0.83 |
| Weighted avg. shares (diluted) | 16.39M | 9.22M |
| Banking | ||
| Net interest income | -$8,240 | -$3,193 |
| Balance sheet | ||
| Cash & equivalents | $654,783 | $574,485 |
| Short-term investments | $3.07M | $2.91M |
| Receivables | $81,571 | $13,043 |
| Inventory | $131,473 | $174,578 |
| Current assets | $4.30M | $3.96M |
| Intangibles | $336,049 | $260,727 |
| Total assets | $4.64M | $4.22M |
| Current liabilities | $887,333 | $546,694 |
| Total liabilities | $887,333 | $546,694 |
| Shareholders' equity | $3.75M | $3.68M |
| Shares outstanding | 639,544 | 13.30M |
| Cash flow statement | ||
| Operating cash flow | -$4.96M | -$3.94M |
| Investing cash flow | -$131,991 | -$577,539 |
| Financing cash flow | $5.17M | $4.52M |
| Stock-based compensation | $3.12M | $3.56M |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.